Vipul C. Chitalia, M.D., Ph.D.
Associate Professor
Boston University Chobanian & Avedisian School of Medicine
Medicine
Nephrology

MD, Seth G.S. Medical College
MBBS, Lokmanya Tilak Medical College and Hospital
DM, Seth G.S. Medical College



Our laboratory focuses on the role of post-translational modifications of proteins, especially polyubiquitnation of the key mediators of vascular pathologies in diseases such as cancer and renal failure. While these diseases are discrete, several fundamental biological processes remain similar. Through a highly collaborative network, our laboratory harnesses the power of various cellular and molecular biological tools, relevant animal models (zebrafish and mice), computational methods and machine-learning techniques and strives to validate these findings and hypotheses in humanized models or human samples from large data bases, which highlights the translational nature of our approach.

A. Vascular diseases in kidney failure: Close to 20 million Americans or 10% of US population suffer from the chronic kidney disease (CKD). Among plethora of cardiovascular manifestations, CKD patients are particularly at high risk for both venous and arterial thrombosis, especially after vascular injury (endovascular injury such as angioplasty or stents; and surgical injury such as arteriovenous fistula creation) in CKD patients. This area of CKD management warrants urgent investigation due to lack of risk predictors and CKD-specific therapeutic targets.
Renal failure results in the retention of several chemical compounds, which unleash cellular toxicity, and hence called uremic solutes/toxins. While investigating the molecular pathogenesis of uremic toxicity, our laboratory was the first to demonstrate the prothrombotic propensity of indolic uremic solutes, which inhibits the ubiquitination of tissue factor, a bona fide member of the extrinsic coagulation pathway. Further investigation revealed Aryl Hydrocarbon Receptor (AHR) pathway as a critical mediator of tissue factor ubiquitination and thrombosis. Leveraging the ligand and the mediator, our lab aims to gain a deeper understanding into the mechanism of this unique uremic thrombosis axis (uremic solutes- AHR- TF- thrombosis) and to develop biomarkers and novel compounds to improve the management of the CKD patients with thrombosis after interventions in various vascular beds including coronary artery and arteriovenous fistula, etc.
Thrombosis being a dynamic and the multicomponent process, our laboratory has taken a holistic approach, under the co-directorship of Drs. Chitalia and Ravid, the Department of Medicine of BUSM and established a Thrombosis and Hemostasis ARC, which is a multidisciplinary platform of cell and molecular biologists, clinicians (cardiologists, vascular medicine, nephrologists and hematologists), computational biologists, biomedical engineers and statisticians and mathematicians to investigate various facets of thrombosis. http://www.bumc.bu.edu/evanscenteribr/the-arcs/the-arcs/

B. Angiogenesis: Angiogenesis, a process of generation of novel blood vessel is fundamental during the development and in various diseases such as cancer. Wnt signaling, a highly conserved oncogenic pathway is critical in angiogenesis. Beta catenin is the prime mediator of Wnt activation. Focusing on the ubiquitination and proteasomal degradation of beta catenin, our previous work had described Jade-1, as an E3 ligases of wild-type beta catenin. Our recent efforts have specifically focused on c-Cbl as an E3 ligase for the mutant beta catenin and for the transcriptionally active beta catenin in the nucleus. These two species of beta catenin, once considered resistant to degradation are effectively downregulated by c-Cbl. Thus, c-Cbl is a unique E3 ligase of tumorigenic beta catenin, which is involved in several cancers including colorectal cancer pathogenesis. Leveraging the cancer animal models and human cancer samples including machine learning based quantitative histology! techniques, our group investigates the colorectal cancer pathogenesis to gain deeper understanding of the role of E3 ligases of beta catenin E3 ligases in various cancers.

Member
Boston University
Whitaker Cardiovascular Institute


Member
Boston University
Evans Center for Interdisciplinary Biomedical Research


Graduate Faculty (Primary Mentor of Grad Students)
Boston University Chobanian & Avedisian School of Medicine, Graduate Medical Sciences





Cancer-Associated Thromboembolism as Affected by Health Disp
07/01/2021 - 06/30/2025 (PI)
Boston University School of Medicine American Heart Assoc

Role of intravascular ultrasound in Central Venous Stenosis in ESRD patients
07/01/2020 - 05/31/2022 (PI)
NIH-NIDDK
1R21DK119740-01A1

Thrombotic complication of uremia: role of prothrombotic uremic solutes
03/16/2016 - 08/31/2021 (PI)
NIH-NHLBI
5R01HL132325-04

Role of c-Cbi in Colon Cancer
07/01/2014 - 04/30/2020 (PI)
NIH-NCI
5R01CA175382-05

Role of thrombosis in Calciphylaxis
07/01/2019 - 10/01/2019 (PI)
Mass General Hosp American Society of

Role of Wnt Signaling in Uremia-induced Endothelial Dysfunction
06/14/2009 - 06/30/2014 (PI)
NIH-NIDDK
5K08 DK080946-04

Role of Wnt Signaling in uremia-induced endothelial dysfunction
07/01/2009 - 06/30/2013 (PI)
National Kidney Fdtn

Role of Jade-1 in Wnt Signaling
07/01/2006 - 06/30/2008 (PI)
Polycystic Kidney Disease Fdtn

Research Fellowship--Polycystic Kidney Disease
07/01/2003 - 06/30/2005 (PI)
National Kidney Fdtn


Title


Yr Title Project-Sub Proj Pubs
2023 Disease-specific risk factors for thrombosis following vascular interventions 1R01HL166608-01A1
2023 Frequency domain shortwave infrared spectroscopy (FD-SWIRS) for volume status monitoring during hemodialysis in end stage kidney disease 5R21DK132784-02
2023 The Boston University Kidney and Medical Engineering Program (BU-KIDMEP) 5R25DK128858-03
2022 Frequency domain shortwave infrared spectroscopy (FD-SWIRS) for volume status monitoring during hemodialysis in end stage kidney disease 1R21DK132784-01
2022 The Boston University Kidney and Medical Engineering Program (BU-KIDMEP) 5R25DK128858-02
2021 The Boston University Kidney and Medical Engineering Program (BU-KIDMEP) 1R25DK128858-01
2021 Role of intravascular ultrasound in Central Venous Stenosis in ESRD patients 5R21DK119740-02
2020 Role of intravascular ultrasound in Central Venous Stenosis in ESRD patients 1R21DK119740-01A1
2019 Thrombotic complication of uremia: role of prothrombotic uremic solutes 5R01HL132325-04 18
2018 Thrombotic complication of uremia: role of prothrombotic uremic solutes 5R01HL132325-03 18
Showing 10 of 22 results. Show All Results

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Budbazar E, Sulser Ponce De Leon S, Tsukahara Y, Liu H, Huangfu Y, Wang Y, Seabra PM, Yang X, Goodman JB, Wan X, Chitalia V, Han J, Seta F. Redox Dysregulation of Vascular Smooth Muscle Sirtuin-1 in Thoracic Aortic Aneurysm in Marfan Syndrome. Arterioscler Thromb Vasc Biol. 2023 Aug; 43(8):e339-e357.View Related Profiles. PMID: 37288573
     
  2. Martens KL, Li A, La J, May SB, Swinnerton KN, Tosi H, Elbers DC, Do NV, Brophy MT, Gaziano JM, Lotfollahzadeh S, Chitalia V, Ravid K, Fillmore NR. Epidemiology of Cancer-Associated Venous Thromboembolism in Patients With Solid and Hematologic Neoplasms in the Veterans Affairs Health Care System. JAMA Netw Open. 2023 Jun 01; 6(6):e2317945.View Related Profiles. PMID: 37306999; PMCID: PMC10261992; DOI: 10.1001/jamanetworkopen.2023.17945;
     
  3. Lotfollahzadeh S, Xia C, Amraei R, Hua N, Kandror KV, Farmer SR, Wei W, Costello CE, Chitalia V, Rahimi N. Inactivation of Minar2 in mice hyperactivates mTOR signaling and results in obesity. Mol Metab. 2023 Jul; 73:101744.View Related Profiles. PMID: 37245847; PMCID: PMC10267597; DOI: 10.1016/j.molmet.2023.101744;
     
  4. Li A, May SB, La J, Martens KL, Amos CI, Flowers CR, Do NV, Brophy MT, Chitalia V, Ravid K, Gaziano JM, Fillmore NR. Venous thromboembolism risk in cancer patients receiving first-line immune checkpoint inhibitor versus chemotherapy. Am J Hematol. 2023 Aug; 98(8):1214-1222.View Related Profiles. PMID: 37161855
     
  5. Wen W, Portales-Castillo I, Seethapathy R, Durant O, Mengesha B, Krinsky S, Kroshinsky D, Kalim S, Goverman J, Nazarian RM, Chitalia V, Malhotra R, Kramann R, Malhotra CK, Nigwekar SU. Intravenous Sodium Thiosulphate for Calciphylaxis of Chronic Kidney Disease: A Systematic Review and Meta-analysis. JAMA Netw Open. 2023 Apr 03; 6(4):e2310068. PMID: 37099293; PMCID: PMC10134003; DOI: 10.1001/jamanetworkopen.2023.10068;
     
  6. Wen W, Portales-Castillo I, Seethapathy R, Krinsky S, Kroshinsky D, Kalim S, Goverman J, Nazarian RM, Chitalia V, Malhotra R, Kramann R, Malhotra CK, Nigwekar SU. Intravenous sodium thiosulphate for vascular calcification of hemodialysis patients-a systematic review and meta-analysis. Nephrol Dial Transplant. 2023 Feb 28; 38(3):733-745. PMID: 35521751; PMCID: PMC10111152; DOI: 10.1093/ndt/gfac171;
     
  7. Zhang M, Lotfollahzadeh S, Elzinad N, Yang X, Elsadawi M, Gower A, Belghasem M, Shazly T, Kolachalama VB, Chitalia V. Alleviating iatrogenic effects of paclitaxel via anti-inflammatory treatment. Res Sq. 2023 Jan 30.View Related Profiles. PMID: 36778300; PMCID: PMC9915804; DOI: 10.21203/rs.3.rs-2487922/v1;
     
  8. Wen W, Krinsky S, Kroshinsky D, Durant O, He J, Seethapathy R, Hillien SAS, Mengesha B, Malhotra R, Chitalia V, Nazarian RM, Goverman J, Lyons KS, Nigwekar SU. Patient-Reported and Clinical Outcomes Among Patients With Calciphylaxis. Mayo Clin Proc Innov Qual Outcomes. 2023 Feb; 7(1):81-92. PMID: 36712824; PMCID: PMC9880339; DOI: 10.1016/j.mayocpiqo.2022.12.006;
     
  9. Li A, La J, May SB, Guffey D, da Costa WL, Amos CI, Bandyo R, Milner EM, Kurian KM, Chen DCR, Do NV, Granada C, Riaz N, Brophy MT, Chitalia V, Gaziano JM, Garcia DA, Carrier M, Flowers CR, Zakai NA, Fillmore NR. Derivation and Validation of a Clinical Risk Assessment Model for Cancer-Associated Thrombosis in Two Unique US Health Care Systems. J Clin Oncol. 2023 Jun 01; 41(16):2926-2938.View Related Profiles. PMID: 36626707; PMCID: PMC10431461; DOI: 10.1200/JCO.22.01542;
     
  10. Lotfollahzadeh S, Zhang M, Napoleon MA, Yin W, Orrick J, Elzind N, Morrissey A, Sellinger IE, Stern LD, Belghasem M, Francis JM, Chitalia VC. A Retrograde Implantation Approach for Peritoneal Dialysis Catheter Placement in Mice. J Vis Exp. 2022 07 20; (185).View Related Profiles. PMID: 35938794; DOI: 10.3791/63689;
     
Showing 10 of 105 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 98 publications over 22 distinct years, with a maximum of 12 publications in 2019

YearPublications
19941
19973
19981
19993
20012
20021
20051
20082
20102
20112
20122
20133
20148
20155
20162
20179
20186
201912
202011
20217
20226
20239

2016 Boston University : Outstanding Mentor award for UROP mentoring
2015-2017 Boston University School of Medicine: Evan’s Junior Faculty Merit Award
2007 Boston University School of Medicine: Annual Evan’s Research Day award
2005 Boston University School of Medicine: Annual Evan’s Research Day award
1998-1999 International Society of Nephrology: International Society of Nephrology Fellowship award
1995 University of Bombay: Gold medal Postdoctoral examination in Nephrology
1990-1992 University of Bombay: Merit Scholarship, Government of India
1987 University of Bombay: Charles Moorhead Prize
In addition to these self-described keywords below, a list of MeSH based concepts is available here.

Chronic Kidney Disease
E3 Ubiquitin Ligase
Thrombosis
Uremic Vascular Disease
Wnt Signaling

I am an Assistant Professor of Medicine at Boston University School of Medicine and an affiliate of Biomedical Engineering at Harvard-MIT Division of Science and Technology, MIT. I am also an attending nephrologist covering renal consults and dialysis and kidney transplant in-patients services at Boston Medical Center. Teaching is my passion and I consider it as my honor to be able to contribute in the training of next generation of physicians, scientists and physician-scientists. I strongly believe that a true mentor is one who inspires passion from within and empowers a mentee to find his or her own path of success. Spanning over entire spectrum, our laboratory has trained several undergraduate students, graduate students and post doctoral fellows, of which several are clinical fellows from renal, cardiovascular and hematology-oncology specialties. Our laboratory has not only US researchers, but has students and post doctoral fellows from Europe, Middle East and Asia creating a truly international learning environment. I have been awarded 2016 Outstanding Mentor Award from the undergraduate research opportunity program (UROP) of Boston University and been nominated for best research mentoring award at BUSM.

Available to Mentor as: (Review Mentor Role Definitions):
  • Advisor
  • Career Mentor
  • Education Mentor
Contact for Mentoring:
  • Email (see 'Contact Info')

650 Albany St Evans Biomed Research Ctr
Boston MA 02118
Google Map


Chitalia's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Media Mentions
_
Co-Authors
_
Similar People
_
Same Department